Zachariah DeFilipp

Mar 15, 2024 | onclive.com | Zachariah DeFilipp

Safety and Efficacy of Axatilimab in Patients With Chronic Graft-Versus-Host Disease (AGAVE-201)Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).

Oct 11, 2023 | nature.com | Zachariah DeFilipp |Yi-Bin Chen |Areej El-Jawahri |Mark Leick

This is a preview of subscription content, access via your institution Access options Subscribe to this journalReceive 12 print issues and online access$259.00 per yearonly $21.58 per issueRent or buy this articlePrices vary by article typefrom$1.95to$39.95Prices may be subject to local taxes which are calculated during checkout ReferencesLuznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al.